RESEARCH



Open Access

A Model for Collaborative Curation, The IEDB and **ChEBI Curation of Non-peptidic Epitopes**

Randi Vita^{1*}, Bjoern Peters¹, Zara Josephs², Paula de Matos², Marcus Ennis², Steve Turner², Christoph Steinbeck², Emily Seymour¹, Laura Zarebski¹, and Alessandro Sette¹

Abstract

The Immune Epitope Database (IEDB) recently expanded and enhanced its non-peptidic epitope related data utilizing a collaboration with Chemical Entities of Biological Interest (ChEBI), resulting in the first resource that brings together published immunological data with the expertise of the ChEBI database. This procedure took advantage of the distinct expertise of the IEDB and ChEBI databases to improve content and enhance interoperability of both databases. This project has resulted in the comprehensive inventory and curation of immune epitope data related to non-peptidic structures and serves as a model for successful collaborative curation between established resources.

Introduction

The important discoveries that make up the scientific literature are hidden within published manuscripts and laboratory notebooks. In order to be fully utilized, this data needs to be converted into the standardized formats of databases and these formats related to non-peptidic epitopes such as carbohyneed to be compatible. There exists a need for experts in each field of curation in order to understand the data being curated. This specialized training can be beneficial across different research specialties if the individual databases collaborate and cooperate. Currently, several collaborative standards exist, such as the Open Biomedical Ontologies (OBO) Foundry [1] and Minimum Information for Biological and Inventory of the literature describing non-Biomedical Investigations (MIBBI) [2]. Here we present a novel collaborative curation method that takes advantage of the specialized curators of two very different databases; the IEDB and ChEBI. This epitope data available to the immunological commucollaboration resulted in enhancements to both datasets and provided new depth and insights to the data tentially containing data that could be curated and being curated.

and T cell epitopes for humans, non-human primates, rodents, and other animal species [3]. To date, was searched utilizing a query, purposely designed curation of peptidic epitope data relating to infec- to be very broad and thus inclusive. The results of tious diseases, allergens, and autoimmunity is com-

¹La Jolla Institute for Allergy and Immunology, Vaccine Discovery, La Jolla, California, USA. ²Chemoinformatics and Metabolism

Team, European Bioinformatics Institute,

Hinxton, Cambridge, UK

Corresponding author: rvita@liai.org

Bjoern Peters bpeters@liai.org Zara Josephs zjosephs@ebi.ac.uk Paula de Matos pmatos@ebi.ac.uk Marcus Ennis mennis@ebi.ac.uk Steve Turner steve.turner@ebi.ac.uk Christoph Steinbeck christoph.steinbeck@ebi.ac.uk Emily Seymour eseymour@liai.org Laura Zarebski laura@liai.org Alessandro Sette alex@liai.org

plete; resulting in the manual curation of 11,641 published manuscripts. Throughout this experience, the IEDB has undergone major revision and expanded its database fields, features, and curation guidelines to ensure accurate, thorough, and consistent curation of peptidic epitope data. However, data drates, lipids, and chemicals were largely uncurated. In order to expand the content of the IEDB to include non-peptidic epitopes we reached out to the experts studying these epitopes and began a fruitful collaboration with the ChEBI resource.

Results

peptidic immune epitopes

As a first step towards making non-peptidic nity and scientific community in general, papers poentered in the IEDB were inventoried. To this end The IEDB contains data related to antibody we adapted an approach already described and validated elsewhere [4]. Briefly, the PubMed database this guery were then narrowed to select potentially relevant papers, by the use of an automated text classifier. This automated classifier was trained on 20,910 abstracts that were manually assigned to be curatable or not by a domain expert. The automated classifier is used to discard all references that with 95% confidence do not contain curatable information. The remaining references are manually reviewed by a domain expert to select the curatable ones. These manual assignments are used to continuously update the automated classifier, resulting in its continuous improvement [5]. As of October 1st 2010,



a total of 27,636 potentially relevant references were identified and categorized as a function of subject matter. Of those, 2,642 related to HIV research were not scrutinized further, as HIV is currently outside of the scope of the IEDB. The remaining 24,994 references categorized as described in Davies et al [4] were separated based on whether they described peptidic or nonpeptidic epitopes. As shown in Figure 1, it was found that 20% of the references identified in PubMed describe non-peptidic epitopes. While the majority (80%) of the literature describes peptidic epitopes, this large proportion of non-peptidic epitopes was notable and unexpected.

Next, we probed in more detail the nature these references [Figure 2]. As done previ-

sified first and foremost on the basis of their associa- example complex carbohydrate blood sugar antigens tion to particular diseases and biological processes, and galactose residues involved in xenotransplantaand then also on the basis of the chemical structure tion. Epitopes predominantly recognized in cancer of the epitope itself. Approximately half (56%) of all research include the Tn, Thomsen-Friedenreich, and non-peptidic epitope references relate to specific dis- Lewis antigens, which are also implicated in autoimeases, such as allergic diseases (776 references; munity and transplantation. 15%), autoimmunity (648; 13%), infectious diseases (517; 10%), transplantation (341; 7%) or cancer However, the largest category of non-peptidic refer-(542; 11%). Non-peptidic epitopes related to allergic ences (44%) describe haptens and carbohydrate reactions mostly include molecules involved in con- moieties not directly associated with a particular distact dermatitis, such as nickel or haptens used in ex- ease. These include model epitopes/antigens that are perimental models of allergy. Non-peptidic epitopes used to study fundamental mechanisms of immunity identified in autoimmunity research are mainly lipids (TNP, DNP, ABA, NIP) and other small molecules and glycolipids. Example structures include cardi- such as natural hormones, narcotics, drugs and their olipin and phosphatidic acid. Infectious disease ref- metabolites, pollutants, poisons, and other assorted erences mostly describe carbohydrate and glycolipid small molecules for which detection assays are being epitopes such as LPS and glycosylated proteins. A developed.



IMMUNOME RESEARCH



ously for peptidic epitopes, the references were clas- references related to transplantation, including for

number of non-peptidic epitopes are discussed in The relative distribution of references relating to non

-peptidic epitopes in comparison to references describing peptidic epitopes also revealed some striking differences. Most notably about 46% of peptidic references are related to infectious diseases, compared to about 10% for non-peptidic. Conversely, only about 13% of the peptidic references are related to model antigens and other molecules, compared to about 44% for non-peptidic. These large differences in distribution are likely the reflection of the widespread use of welldefined small haptens to study immune responses, especially in early immunological literature, combined with the technical challenges associated with the exact definition of non-peptidic epitopes recognized in infectious diseases. In

conclusion, a large fraction of the immunological literature describes epitopes that are non-peptidic.

Representing non-peptidic data in the IEDB identification through free text and alpha-numeric

Having identified references within the IEDB scope uniform. In different references the same chemical and their relative subject matter, we next determined entity can be described by its molecular formula, its to what extent the existing database structure was simplified molecular input line entry specification amenable to the representation of non-peptidic epi- (SMILES), its 3-D rendering, a common name, a topes and what changes or modifications might be commercial name or a variety of chemical nomennecessary. By comparison, describing peptide epi- clatures such as IUPAC. Fortunately and coincidentopes is relatively straightforward, with the ability to tally, the ChEBI initiative had already been generatdescribe both continuous and discontinuous epitopes ing a framework where IUPAC names, 3-D strucusing the standard single letter code for amino acid tures, a structural hierarchy, and a list of synonyms sequences. In terms of nomenclature, in the case of for non-peptidic structures can be provided for small peptidic epitopes simple BLAST searches allow as- molecules [6]. Our interest in linking and integrating signment of source proteins, taking advantage of the IEDB data to this type of information mirrored existing web resources, such as Genbank.

ers who had authored publications describing non- potential for synergy, a formal collaboration began peptidic epitopes. Two main points emerged from in June of 2009. their collective feedback. First, since the types of molecules studied included a wide variety of chemi- Establishment of an Effective Curation Proccal entities such as polysaccharides, drugs, haptens, ess metals, and glycolipids, they recommended using classification systems including generic names and The next task was to put in place a process for cura-IUPAC. Second, search options could include ge- tion of the nonpeptidic epitope data. Figure 3 preneric names, InChI strings, CAS numbers, and the sents the work flow with initial review by the IEDB drawn structure. No modifications were deemed nec- staff of a given reference to identify the immunoessary to the existing database structure to represent gens, antigens, and epitopes. This information is then the immune responses recognizing the epitopes, the transferred to a dedicated ChEBI curator to generate host, immunization and assay-related fields.

IMMUNOME RESEARCH

Indeed, by far the most challenging aspect relating to the curation of non-peptidic epitopes is the representation of their molecular structure and identifiers. The commonly used nomenclature is not an interest from the ChEBI project, in linking immu-We began by contacting approximately 50 research- nological data to its database. Based on the strong

new ChEBI entries, utilizing a shared spreadsheet format. The ChEBI curator then locates the



structures the IEDB curator identified, and determines if it already exists on the ChEBI website. If it does, the existing entry is enhanced by including any new names or synonyms to which the manuscript referred, citation to the particular manuscript, the role(s) played by that entity in that manuscript, and updates any other information in the entry as needed. Alternatively, if the structure does not already exist on the ChEBI site, an entirely new entry is produced. The new information that has been added to ChEBI is released with each scheduled build of the ChEBI website. The ChEBI curator then supplies the IEDB curator with the correct ChEBI ID per requested structure via the shared spreadsheet. An example of

a ChEBI entry curated on behalf of the IEDB is shown in Figure 4. In this figure, amoxicillin, a commonly recognized allergy epitope, is represented in the following formats: 3-D drawing, IUPAC International Chemical Identifier (InChI), SMILES, and chemical formula. Additional information present on the ChEBI website such as synonyms, brand names, and ontological relationships, as well as numerous external links is shown in Figures 5 and 6.

noxicillin (C	CHEBI:2676)			Quick search here! GO
Main	Automatic X	(refs		Search for Transformer only
		ChEBI Name 🔞	amoxicillin	
			CHEBI:2676	
		Definition 0	A penicillin in which the substituent at positi	ion 6 of the penam ring is a 2-amino-
	N S	the Loot Medified 0	2-(4-hydroxyphenyl)acetamido group.	
но				
	Лон		CUERICACONA CUERICATIONS OF THE CONTRACT	ated by the ChEBI I eam.
		Secondary ChEBI IDS	CHEBI.243284, CHEBI.473930, CHEBI.133	3770
		Image		
Molfile				
		more structures >>		
nChl 🕜 📄	InChl=1, 2H3,(H,	/C16H19N3O5S/c1-16(2)11(18,21)(H,23,24)/t9-,10-,11+,1	(15(23)24)19-13(22)10(14(19)25-16)18-12(2 14-/m1/s1/f/h18,23H	1)9(17)7-3-5-8(20)6-4-7/h3-6,9-11,14,20H,17H2,1-
nChlKey 🛛 📄	InChiKe	y=LSQZJLSUYDQPKJ-VLWI	BPTPADT	
<u>SMILES</u> 🛛 🗎	[H][C@]	12SC(C)(C)[C@@H](N1C(=(0)[C@H]2NC(=0)[C@H](N)c1ccc(0)cc1)C(0)	=0
Formula 🕜				Source
C16H19N3O5S	i			ChEBI
Charge 🕜	0			
gure 4. A	365.404 An Immune e	epitope as preser	nted on the ChEBI website	.
igure 4. A	365.404	epitope as preser	nted on the ChEBI website	÷.
igure 4. A	365.404	oo epitope as preser	nted on the ChEBI website	÷.
igure 4. A	365.404	bis conjugate acid of amoxid is a pericillin (CHEB:17334)	nted on the ChEBI website	ð.
Mass gure 4. A ChEBI Ontology (ChEBI Ontolo	365.404	bis conjugate acid of amoxia lis conjugate acid of amoxia lis a penicillin (CHEB:17334) 1256) is conjugate base of a 1255/1250 is substituent grou BI:53712) is substituent grou BI:53713) is substituent grou BI:53713) is substituent grou BI:53712) is substituent grou	cillin(1-) (CHEBI:51256) amoxicillin (CHEBI:5276) in (CHEBI:2676) pp from amoxicillin (CHEBI:2676) up from amoxicillin (CHEBI:2676) pp from amoxicillin (CHEBI:2676) p form amoxicillin (CHEBI:2676)	÷.
Igure 4. A ChEBI Ontology ChEBI Ontology Tree view Dutgoing am am am am am am am am am am	365.404	epitope as presei is conjugate acid of amoxi is a penicillin (CHEBI-17334) 1255) is conjugate base of a IEBI-51254) has part amoxicill 81:53703) is substituent grou BI-53712) is substituent grou CHEBI-55470) has functiona	cillin(1-) (CHEBI:51256) amoxicillin (CHEBI:2676) In (CHEBI:2676) Up from amoxicillin (CHEBI:2676) Up from amoxicillin (CHEBI:2676) I parent amoxicillin (CHEBI:2676)	ð.
Mass gure 4. A ChEBI Ontology ChEBI Ontology ChEBI Ontology and and and and and and and and	365.404	bis conjugate acid of amoxid is conjugate acid of amoxid is a penicillin (CHEBI:17334) 1256) is conjugate base of a EBI:51254) has part amoxidi BI:53713) is substituent grou CHEBI:55470) has functiona retamidoj-2,2-dimethylpenam-3	nted on the ChEBI website) .
Mass gure 4. A thEBI Ontology thEBI Ontology thEBI Ontology am am am am am am am am am am	365.404	epitope as preser is conjugate acid of amoxid is a penicillin (CHEBI:17334) 1256) is conjugate base of a EBI:51254) has part amoxidi BI:53713) is substituent grou EBI:53713) is substituent grou CHEBI:55470) has functiona	nted on the ChEBI website	Э.
Mass gure 4. A chEBI Ontology the the the the the the the the the the	365.404	epitope as preser is conjugate acid of amoxid is a penicillin (CHEBI:17334) 1256) is conjugate base of a EBI:51254) has part amoxidi BI:53713) is substituent grou CHEBI:55470) has functiona retamidoj-2,2-dimethylpenam-3	cillin(1-) (CHEBI:51256) amoxicillin (CHEBI:51256) in (CHEBI:2676) in (CHEBI:2676) in (CHEBI:2676) ip from amoxicillin (CHEBI:2676) ip prom amoxicillin (CHEBI:2676) is parent amoxicillin (CHEBI:2676) sa-carboxylic acid	plus RUG
Mass gure 4. A chEBI Ontology the EBI Ontology the eview and and and and and and and and	365.404	epitope as preset	cillin(1-) (CHEBI:51256) amoxicillin (CHEBI:52576) in (CHEBI:26776) in (CHEBI:26776) in (CHEBI:26776) ip from amoxicillin (CHEBI:26776) ip prom amoxicillin (CHEBI:26776) ip parent amoxicillin (CHEBI:26776) is parent amoxicillin (CHEBI:26776) is carboxylic acid	plus RUG plus
Mass igure 4. A chEBI Ontology Tree view Dutgoing an an an an an an an an an an	365.404	epitope as preser	nted on the ChEBI website	Plus Plus
Mass igure 4. A ChEBI Ontology ChEBI Ontology Tree view Dutgoing am am am am UPAC Name isP(2/A)-2-amino- NNS isP(2/A)-2-amino- NNS isP(2/A)-2-amino- Source isP(2/A)-2-amino-	365.404	epitope as preser is conjugate acid of amoxid is a pericillin (CHEBI:17334) 1256) is conjugate base of a 1255/1265) has part amoxid 1253/126 is substituent grou 1253/126 is substituent grou CHEBI:5126470) has functiona retamido]-2,2-dimethylpenam-3	nted on the ChEBI website	Plus RUG plus i
Mass igure 4. A chEBI Ontology Tree view Dutgoing am am am am am am am am am am	365.404	epitope as preser is conjugate acid of amoxid is a pericillin (CHEBI:17334) 1259) is conjugate base of a 1259 is conjugate base of a 1259 is conjugate base of a 1259 is subsituent grou 1265/12) is subsituent grou CHEBI:55247(a) has functiona retamidoj-2,2-dimethylpenam-3 retamidoj-2,2-dimethylpenam-3 retamidoj-2,2-dimethylpenam-3	anted on the ChEBI website	plus RUG plus plus
Mass gure 4. A chEBI Ontology Tree view and and and and and and and and	365.404	epitope as preser is conjugate acid of amoxid is a pericillin (CHEBI:17334) 1256) is conjugate base of a EBI:512529 has part amoxidill 28:37(3) is substituent grou EBI:5172) is substituent grou EBI:5172) is substituent grou CHEBI:55470) has functiona setamidoj-2,2-dimethylpenam-3 etamidoj-2,2-dimethylpenam-3 mid	nted on the ChEBI website	Plus RUG plus plus plus plus plus
Mass gure 4. A thEBI Ontology thEBI Ontology arreaview arrea	365.404	epitope as preset	nted on the ChEBI website	Plus RUG plus Plus Plus Plus Plus Plus
Mass gure 4. A ChEBI Ontology Tree view Dutgoing an am am am am am am am am am am	365.404	epitope as preset is conjugate acid of amoxi is a penicillin (CHEBI 1733) 1256) is conjugate base of a 1255) is substituent grou 1255) is conjugate base of a 1255) is conjugate ba 1255) is conjugate base of a 1255) is conjugate base of a	nted on the ChEBI website	Plus RUG plus ∎ plus © MPOUND OMPOUND OMPOUND Domes So
Mass gure 4. A chEBI Ontology Tree view butgoing am am am am am am am am am am	365.404	with the second seco	ethyl-7-oxo-4-thia-1-	Plus RUG Plus Plus Plus © MPOUND ∞MPOUND Plus ℃
Mass gure 4. A chEBI Ontology Tree view butgoing an am am am am am am am am am am	365.404	epitope as preset	nted on the ChEBI website	Pius Pius RUG Pius Pius S OMPOUND OMPOUND Pius S OMPOUND Pipus S S OMPOUND Pipus S S
Mass igure 4. A ChEBI Ontology Tree view Dutgoing an am am am am am am am am am am	365.404	epitope as preset	ettlyl-7-oxo-4-thia-1-	≥.
Mass igure 4. A ChEBI Ontology Tree view Dutgoing an am am am am am am am am am am	365.404	epitope as preset	ethyl-7-oxo-4-thia-1-	Plus RUG plus ©MPOUND plus ©MPOUND plus ℃
Mass igure 4. A ChEBI Ontology Tree view Dutgoing an am am am am am am am am am am	365.404	apitope as preset apitope as preset apitope as preset apitope as preset apple apple acid of amoxic apple acid acid apple acid acid apple acid acid	ethyl-7-oxo-4-thia-1- IUPAC ChemiD	Plus Plus RUG Plus
Mass igure 4. A ChEBI Ontology Tree view Dutgoing an am am am am am am am am am am	365.404	uis conjugate acid of amoxidists a periodillo (CHEB):1733-9 1256) is conjugate base of a moxidilla:83706) is substituent groutilla:83706) is substituent groutilla:83706) is substituent groutilla:83713) is substituent groutilla:83713, is substiter groutilla:83713, is substituent grouti	ethiol on the ChEBI website	Plus RUG plus plus sel sel plus sel sel sel sel sel sel sel sel sel se

Database Links		Databases
C06827		KEGG COMPOUND
D07452		KEGG DRUG
DB01060		DrugBank
DE1942693		Patent
GB1241844		Patent
GB978178		Patent
US3192198		Patent
243284		ChEMBL
Registry Numbers	Types	Sources
<u>26787-78-0</u>	CAS Registry Number	ChemIDplus
4274654	Beilstein Registry Number	Beilstein
Citations 0		
[show Abstract] Katsura Y, Tomishi T, Inoue Y, Sa Anti-Helicobacter pylori agents Journal of medicinal chemistry [show Abstract] Danelian E, Karlen A, Karlsson R SPR biosensor studies of the dii Journal of medicinal chemistry	akane K., Matsumoto Y., Morinaga C., Ishikawa H., Taka 4. 4. 2-(Substituted guanidino)-4-phenylthiazoles and 43, 3315-21 (Source: ChEMBL) [PubMed:109667 Winiwarter S., Hansson A., Lofas S., Lennemas H., Har rect interaction between 27 drugs and a liposome su 43, 2083-6 (Source: ChEMBL) [PubMed:1084176	asugi H (2000) d some structurally rigid derivatives. <u>750</u> @ malainen MD (2000) urface: correlation with fraction absorbed in humans. 36Ø
von Greyerz S,Bultemann G,Sch Degeneracy and additional allor International immunology 13, & [show Abstract]	nyder K,Burkhart C,Lotti B,Hari Y,Pichler WJ (2001) reactivity of drug-specific human alpha beta(+) T ce 877-85 [PubMed:114314188]) All clones.
Ando R,Kawamura M,Chiba N (3-(Arylacetylamino)-N-methylbe Journal of medicinal chemistry	(2001) enzamides: a novel class of selective anti-Helicobac 44. 4468-74 (Source: ChEMBL) [PubMed:11728]	ter pylori agents.
[show Abstract]	() () () () () () () () () () () () () (132 09

Figure 6. External links provided on the ChEBI website.

			Epitope Information		
	Distinct	Epitope		ChEBI Image	
	Epitope ID:	112424			
	Name:	2,4-dinitrop	henol		
	Accession:	CHEBI:4201	7	Т. N	
	SMILES Structure:	Oc1ccc(cc1	N(=O)=O)N(=O)=O	0=**>0	
eference (24)	B Cell Assay (14) T Ce	ell Assay (37	0		
4 item(s) found xport all results	, displaying 1 to 24 (Click th : 🛛 (compact full)	ne column he	eaders to adjust the sorting)		
Reference ID	1 Author		Title	Abstract	Summary
322	Leo C James; Pietro Rov Tawfik	versi; Dan S	Antibody multispecificity mediated by conformational diversity.	A single antibody was shown to adopt different binding-site conformations and thereby bind unrelated	Science, 2003
1005582	O Moriya; Y Ichikawa		Elicitation of delayed type hypersensitivity in chicks after in ovo sensitization with different molecular forms of the same hapten.	Lymphocyte sensitization, which participates in delayed type hypersensitivity (DTH) in chick embryos	Microbiol Immunol, 1983
1005626	M C Ray; M D Tharp; T : R E Tigelaar) Sullivan;	Contact hypersensitivity reactions to dinitrofluorobenzene mediated by monoclonal IgE anti-DNP antibodies.	Several studies have suggested a possible role for IgE antibodies in the pathogenesis of cutaneous h	J Immunol, 1983
1007912	H Miyauchi; T Horio		A new animal model for contact dermatitis: the hairless guinea pig.	Allergic and irritant contact reactions were evaluated in the recently identified hairless guinea pi	J Dermatol, 1992
1012055	Y Niwa; H Niwa; J Kohmi Ou; M M Yokoyama	ura; D W	Studies on the dinitrochlorobenzene (DNCB) sensitization test.	One hundred and ninety-nine patients were divided into three groups and examined for their skin reac	Ann Allergy, 1982
1012059	R J Dearman; J M Hegar Kimber	ty; I	Inhalation exposure of mice to trimellitic anhydride induces both IgG and IgE anti-hapten antibody.	The development of antibody responses resulting from inhalation exposure to chemical allergens has b	Int Arch Allergy Appl Immunol, 1991
				Sensitization trials with	

Figure 7. Immune epitope as presented on the IEDB.



Once available, the IEDB reviews each structure and this newly available information. Previously, nonlinks the IEDB website with the ChEBI resource to peptidic epitopes could be searched by a molecule download the required fields (generic name, IUPAC finder which only allowed users to search for nonname, when available, synonyms, molecular struc- peptidic structures by name. This was problematic as ture (SMILES), parent classes), making the newly the nomenclature of these structures is complex, generated ChEBI structure selectable by IEDB cura- variable, and full of synonyms. This issue was retors via an internal 'Molecule Finder' application. solved by a newly developed non-peptidic molecule Once the IEDB curation of the reference is com- finder, where all synonyms and abbreviations are pleted, it appears on the IEDB's external website. An now searchable. example of a ChEBI structure utilized by the IEDB is shown in Figure 7. Here 2,4-dinitrophenol (DNP), a commonly studied hapten epitope, is presented with its ChEBI image, SMILES, name, and ChEBI link, together with the IEDB curated immunological data.

Current Status of Reference curation

As of October 15th 2010, 770 references describing non-peptidic epitopes have been curated on the IEDB throughout this process. This involved 1,220 non-peptidic structures, the replacement of over 300 previously IEDB curated non-peptidic structures with ChEBI curated structures and the assignment of ChEBI parents to all IEDB structures to allow placement in ChEBI's ontological tree, as described in more detail below.

As seen in Table 1, the curation of allergyrelated records is essentially complete, and approximately 30% of the references related to autoimmunity and infectious diseases have been curated. After completion of the references included in these two categories, transplant related references will be addressed followed by model antigen references. The curation of cancer epitope references is not currently within the scope of the IEDB. We envision that these activities will be essentially complete by the end of 2011.

Query and Display

able 1. Curation status of non-peptidic refe

IMMUNOME RESEARCH

The previous sections describe how a process for capturing non-peptidic epitope data was put into where more detailed information on each structure, place and how the curation of references containing including a variety of nomenclatures, links, and citasuch information is in its advanced stages. In paral- tions can be found. lel, it became necessary to redesign the IEDB external site search capabilities, to allow searching for

Number of Relevant Non-Peptidic References							
Main Class	Total	Number	%				
		Curated	Curated				
Infectious Disease	517	155	30				
Allergy	776	700	90				
Autoimmunity	648	244	38				
Transplant	341	8	2				
Model Antigens/Other	2259	15	1				
Total Potentially Relevant	4541	1122	25				

A further advance is the incorporation of a non -peptidic molecule tree that makes use of ChEBI's formal ontology. The ChEBI website provides a structural ontology, grouping together similar structures, such as all carbohydrates or all lipids in a hierarchical fashion. The IEDB incorporated this information in the form of a non-peptidic tree, where all structures are organized and grouped by type. For example, all carbohydrates can be found under the grouping of 'carbohydrate' with additional branches such as 'oligosaccharide', "carbohydrate phosphate', and 'glucosamine'. For example, in the penicillin group while previously each member of the penicillin family had to be searched individually by name, such as 'ampicillin', in the new tree, one may select the entire group of penicillins or individual members.

In this respect the tree allows a search strategy that is analogous and complementary to searches using the NCBI taxonomy tree, already in use in the IEDB, where searches can be performed at the taxonomical level of species, genus, family, and so on as desired. Figure 8 shows this non-peptidic tree structure on the IEDB's search interface, where the lipopolysaccharide (LPS), a commonly recognized infectious disease epitope, is presented as a child of carbohydrate, lipid, and polysaccharide. Accordingly, end users can search for data related specifically to LPS or on all carbohydrate or polysaccharide epitopes. Additionally, newly available information on each non-peptidic structure is now provided via direct links to each structure's ChEBI webpage

Discussion

Herein we present an account of the inventory and curation of immunological information related to well-defined non-peptidic epitopes. To the best of our knowledge, this is the first time this task has been undertaken in a comprehensive and systematic manner. Accordingly, an original solution had to be developed. Finally, the result of this effort highlights a case where considerable synergy can be obtained

by integrating different database resources, each focusing on clearly distinct yet related subject matters.

The inventory of all references related to nonpeptidic epitopes revealed that close to a quarter of all references describing immune epitopes was indeed related to non-peptidic epitopes. This result was surprising and might be reflective of the fact that the relatively low visibility of these references might be related to the absence of comprehensive repositories where this information is cataloged, and most importantly, easily retrieved. In terms of the type of references, as compared to peptidic references, several observations were made. First, model antigens are predominant in the non-peptidic epitopes, reflecting much of the seminal work utilizing model haptens to define basic immune mechanisms. Second, the relatively large number of references relating to allergies, reflect the well-recognized importance of small molecules in terms of causing allergic reactions. Finally, relatively lower numbers of references were found describing non-peptidic epitopes related to infectious diseases and transplantation. This is not necessarily a reflection of the lack of importance of non peptidic epitopes in these settings, but rather is likely due to the technical challenges associated with the considerable chemical complexity of the structures recognized. Thus this might highlight an important opportunity for future research, as the exact definition of these molecules might facilitate the development of new diagnostic or therapeutic approaches.

The main challenges to curation and display of immune epitope non-peptidic data were addressed by developing a curation process that integrated the processes already in place in the IEDB with processes independently developed by the ChEBI initiative. The ChEBI database was first released in 2004 as a database and ontology for chemical entities of biological interest that is a freely available dictionary of molecular entities focused on 'small' chemical compounds. ChEBI is unique in its content as it was developed to fill a niche that it describes as "long neglected by the computational biology/ bioinformatics community." ChEBI contains by far the most data available on non-peptidic structures, however, prior to the IEDB:ChEBI collaboration their immunological relevance as epitopes, immunogens or antigens was not described. In this respect the processes described herein represent an important example of how two different yet related resources can be integrated, realizing significant synergies.

Since the collaboration with ChEBI begun in 2009, curation of non-peptidic references has been swift, with complete curation of these references

expected by the end of 2011. As a result, the IEDB now is a comprehensive resource for non-peptidic epitope information. Data that was previously embedded in the literature and described utilizing a wide variety of disparate nomenclature is now collected in the IEDB in a standardized and easily searchable manner. In addition, these structures are also present in the ChEBI resource with additional metadata such as citations and roles the structures can play. This represents a significant accomplishment, as only few web-based, freely available resources for non-peptidic structures are available [7]. Available online resources have historically been skewed towards peptidic/protein-based research with a variety of publically available resources such as the GenBank and Uni-prot databases.

Following the development of an efficient curation process that allows simplified curation and query of non-peptidic structures, the IEDB plans to further enhance the database to include new features. One such enhancement could allow searching for non-peptidic structures by way of the roles that they play in chemistry, immunology, and medicine. The ChEBI database provides this information for every entry and includes such roles as pesticide, antimicrobial, acid, catalyst, analgesic, etc. This information could be added to the IEDB query interface to enhance the database content and increase flexibility of search parameters. Additionally, interoperability between the ChEBI and the IEDB will be increased by linking ChEBI structures utilized by the IEDB to its epitope information on the IEDB's website later this year.

In conclusion, a curation process has been designed to specifically address non-peptidic epitopes. This process capitalized on the distinct knowledge and expertise of the IEDB and ChEBI databases and resulted in improved content with newly curated ChEBI structures and IEDB non-peptidic epitopes, as well as enhanced interoperability via direct links between the websites and the integration of ChEBI's standardized nomenclature and ontology into the IEDB's search interface. The IEDB and ChEBI initiative has resulted in a comprehensive inventory and curation of immune epitope data related to non-peptidic structures. This integration allows rigorous yet user-friendly retrieval of the data and it is envisioned that it will ultimately facilitate both basic and applied research related to fields as diverse as model antigens, infectious disease, allergies, autoimmunity and transplantation.





COMPETING INTERESTS

The authors declare that they have no competing interests.

AUTHORS' CONTRIBUTIONS

ES, LZ, ZJ, PdM, ME, ST, and CS contributed to acquisition of data, drafting and revising the manuscript, and gave final approval of the version to be published.

BP and AS contributed to the conception and design of the manuscript, analysis and interpretation of the data, drafting and revising the manuscript, and gave final approval of the version to be published.

RV is the corresponding author and contributed to the conception and design of the manuscript, acquisition of data, analysis and interpretation of the data, drafting and revising the manuscript, and gave final approval of the version to be published.

ACKNOWLEDGMENTS AND FUNDING

The IEDB is funded by The National Institutes of Health/National Institute of Allergy and Infectious Diseases, Immune Epitope Database (contract number: HHSN2662004000 0 6C), under the Immune Epitope Database and Analysis Program.

We would like to thank these experts in the study of non-peptidic epitopes: Brian A Baldo, Andrea Cavani, Betty Diamond, Uri Galili, Eon N Harris, Christoph Helma, Kim D. Janda , Dennis L. Kasper, Stefan F. Martin, Werner J. Pichler, Liise-anne Pirofski, Mireille Sebbag, Rene Toes, and Dirk Zajonc.

REFERENCES

1. Smith B, Ashburner M, Rosse C, Bard C, Bug W, Ceusters W, Goldberg L J, Eilbeck K, Ireland A, Mungall C J, The OBI Consortium, Leontis N, Rocca-Serra P, Ruttenberg A, Sansone S-A, Scheuermann R H, Shah N, Whetzel P L and Lewis S: The OBO Foundry: coordinated evolution of ontologies to support biomedical data integration. Nature Biotechnology 2007, 25, 1251-1255. http://www.ncbi.nlm.nih.gov/sites/ ppmc/articles/PMC2814061/

2. Taylor CF, Field D, Sansone SA, Aerts J, Apweiler R, Ashburner M, Ball CA, Binz PA, Bogue M, Booth T, Brazma A, Brinkman RR, Michael Clark A, Deutsch EW, Fiehn O, Fostel J, Ghazal P, Gibson F, Gray T, Grimes G, Hancock JM, Hardy NW, Hermjakob H, Julian RK Jr, Kane M, Kettner C, Kinsinger C, Kolker E, Kuiper M, Le Novère N,

Leebens-Mack J, Lewis SE, Lord P, Mallon AM, Marthandan N, Masuya H, McNally R, Mehrle A, Morrison N, Orchard S, Quackenbush J, Reecy JM, Robertson DG, Rocca-Serra P, Rodriguez H, Rosenfelder H, Santoyo-Lopez J, Scheuermann RH, Schober D, Smith B, Snape J, Stoeckert CJ Jr, Tipton K, Sterk P, Untergasser A, Vandesompele J, Wiemann S: Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project. Nat Biotechnol 2008 Aug;26(8):889-96.

3. Vita R, Zarebski L, Greenbaum JA, Emami H, Hoof I, Salimi N, Damle R, Sette A, Peters B: The immune epitope database 2.0. Nucleic Acids Res. 2010 Jan;38 (Database issue):D85462. http:// www.ncbi.nlm.nih.gov/sites/ppmc/articles/PMC2808938/

4. Davies V, Vaughan K, Damle R, Peters B, Sette A: Classification of the universe of immune epitope literature: representation and knowledge gaps. PLoSOne 2009 Sep 14;4(9):e6948. http:// www.ncbi.nlm.nih.gov/sites/ppmc/articles/PMC2747625/

5. Wang P, Morgan AA, Zhang Q, Sette A, Peters B: Automating document classification for the Immune Epitope Database. BMC Bioinformatics 2007 Jul 26;8:269. http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC1965490/

6. de Matos P, Alcántara R, Dekker A, Ennis M, Hastings J, Haug K, Spiteri I, Turner S, Steinbeck C: Chemical entities of biological interest: an update. Nucleic Acids Res 2010 Jan;38 (Database issue):D249-54. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808869/

7. Kawasaki T, Nakao H, Tominaga T: GlycoEpitope: A Database of Carbohydrate Epitopes and Antibodies. Experimental Glycoscience 2008 Part 4, Section XXIII, 429-431.

